Octave Bioscience

Octave Bioscience is a privately held biotechnology company headquartered in Menlo Park, California. Founded in 2014, the company focuses on precision neurology, combining blood-based biomarkers, data analytics, and clinical insights to improve the management of complex neurological conditions. Its initial focus is multiple sclerosis (MS), a chronic disease in which monitoring disease activity and evaluating treatment response can be challenging. Octave aims to provide clinicians with more objective information to support patient management and treatment decisions.

The company’s principal commercial product is the Octave MS Disease Activity (MSDA) Test, a multi-protein blood test designed to measure biomarkers associated with MS disease activity and produce a quantitative score. The test is supported by clinical research and is available nationally through a collaboration with Quest Diagnostics. Octave is also developing additional biomarker-based approaches for MS disease progression and Parkinson’s disease, extending its platform into other neurodegenerative conditions.

Octave works across the healthcare and life sciences ecosystem, including clinicians, health systems, research organizations, diagnostic partners, and patient advocacy groups. Its strategy centers on making complex biological information more useful for clinical decisions and advancing more personalized neurological care. With leadership spanning biotechnology, diagnostics, commercial strategy, marketing, and market access, the company operates at the intersection of precision medicine, laboratory diagnostics, and healthcare technology.